Olmesartan (Benicar) and kidney disease

As a matter of course, markers of kidney function including blood urea nitrogen (BUN) and creatinine will fluctuate while a patient is on the Marshall Protocol (MP).

There is a tendency for some physicians to become alarmed by these fluctuations, particularly if a patient has kidney disease. However, for the vast majority of patients these test results are an expected part of the healing process. In fact, a wide range of research shows that olmesartan is therapeutic for kidney disease.

High BUN is an indication of a successful immune response

One study found that hemodialysis patients who had high serum values of urea nitrogen (BUN) were less likely to have the acute infection, Helicobacter pylori.1) This suggests that temporary markers of kidney stress such as BUN may correlate with a robust and successful immune response.

Vitamin D Receptor activation increases creatinine production

In a 2011 study appearing in Kidney International, Agarwal et al. gave 16 patients with chronic kidney disease daily doses of paricalcitol, an orally active vitamin D receptor activator.2) The vitamin D analog was stopped after four days, and measurements were continued for three. Researchers found that subjects' serum creatinine significantly increased at a rate of 0.010 mg/dl/day and urine creatinine at a rate of 17.6 mg/day. Researchers also found a small increase in blood levels of BUN.

In conclusion, VDR activation may alter creatinine metabolism. An increase in creatinine generation may lead to an increase in serum creatinine and, if eGFR is used to measure kidney function, it may give the appearance that kidney function is declining when truly it may not be altered.

Rajiv Agarwal et al.

This in vivo study is significant as it confirms several key aspects of the Marshall Protocol:3)

  • Patients with kidney disease on a treatment designed to stimulate the VDR can expect their measures of creatinine to increase.
  • The strategy of waiting-out abnormal creatinine values, rather than trying to intervene, is the most sensible approach currently available.
  • A more valid method for measuring kidney function is the 24hr creatinine clearance test, rather than the calculated eGFR.

Elevated kidney values tend to be temporary

Typically, the levels of BUN - a measure of the amount of nitrogen in the blood that comes from urea, a substance removed by the kidneys - to come back elevated, as bacterial endotoxins cause nitric oxide and subsequently more nitrogen to be generated in the inflamed tissues. Levels of creatinine - a breakdown product of phosphate that is filtered by the kidneys - may also become elevated after people start the MP. This is not unusual, as most short courses of antibiotics aimed at killing classical bacteria also cause spikes in BUN and creatinine. According to the study site, maintaining a level of creatinine 10-20% higher than normal indicates the kidneys are functioning adequately while the MP is inducing immunopathology to resolve kidney inflammation.

The important thing to keep in mind is that these markers fall back into range as the disease resolves and the Th1 pathogensThe community of bacterial pathogens which cause chronic inflammatory disease - one which almost certainly includes multiple species and bacterial forms. are eradicated. Remaining on olmesartan despite fluctuations in markers of kidney and liver function is therapeutic and a necessary part of the healing process.

In the patient with an increase in serum creatinine concentration, decreasing the dose of [the ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor.]… will cause the serum creatinine concentration to return to the original baseline. Unfortunately, such an approach is not optimal for the long-term preservation of renal function and should be discouraged.

Biff Palmer, Nephrology at the University of Texas Southwestern 4)

“Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function” 5)

Subclinical kidney infection

Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with Th1 diseases, and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the Th1 pathogens. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test.

Once patients activate the innate immune system with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests.

Olmesartan benefits patients with kidney disease

According to a 2008 commentary appearing in Nature:

Vitamin D receptor (VDR) activation has a beneficial influence on the progression of experimental renal insufficiency, and reduced renal tissue renin expression may play a role in this process.

Ilkka H. Pörsti 6)

MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. damage.

The benefits of olmesartan on patients with kidney inflammation include

  • decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.7)
  • decreased (intra)renal vascular resistance, increased renal perfusion, and significantly reduced oxidative stress in patients with type 2 diabetes8)
  • protection of the kidneys in diabetic nephropathy 9)
  • offer a survival benefit in hemodialysis patients, may help in preservation of renal function in predialysis patient, and affect the tissue repair process, reducing renal fibrosis10)
  • prevention of the onset of microalbuminuria in patients with Type 2 diabetes11) 12) 13) 14)

Benefits of angiotensin receptor blockers

High-dose ARB treatment in patients with chronic renal disease is not associated with any clinically significant long-term negative effects on serum creatinine or potassium and is thus an important therapeutic modality with which to achieve further reductions in urinary protein excretion.

Alan J. Weinberg, et al. 15)

The effects of ARBs, in general, on people with kidney inflammation include:

Olmesartan also has additional beneficial effects for organs and systems beyond the kidneys.

Animal studies

.Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.

Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.21)

Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.22)

===== Notes and comments =====

Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate PMID https://www.sciencedirect.com/science/article/pii/S0085253815549466

  • Legacy content
    • f107 * f80 * f86 * f112 * f113 * f133

Caution for severe dehyration should be included. — Ken Collerman 07.09.2009

“Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?” https://www.ncbi.nlm.nih.gov/pubmed/18695383

Kidney Blood Press Res. 2011 Jun 28;34(6):418-423. [Epub ahead of print] Olmesartan Induces Renoprotective Effects by Stimulating Angiotensin Type 2 Receptors and Reducing Oxidative Stress in Diabetic Nephropathy.

Jo F, Morimoto S, Nakahigashi M, Kusabe M, Someya K, Morita T, Jo H, Imada T, Kosaki A, Toyoda N, Nishikawa M, Iwasaka T. Source

Second Department of Internal Medicine, Kansai Medical University, Moriguchi City, Japan.


Background: Angiotensin receptor blockers reduce the progression of diabetic nephropathy primarily by inhibiting angiotensin type 1 (AT(1)) receptors. In the present study, we investigated the role of angiotensin type 2 (AT(2)) receptors on the renoprotective effects of olmesartan in diabetic nephropathy. Methods: Six-week-old mice were treated with streptozotocin and divided into four groups: the OLM group (mice treated with olmesartan), the OLM+Ang II group (mice treated with olmesartan and angiotensin II), the OLM+PD group (mice treated with olmesartan and the AT(2) antagonist PD 123319), and the vehicle group. Nondiabetic mice were used as controls. We measured blood glucose levels and urinary excretions of albumin and 8-hydroxy-2'-deoxyguanosine (8-OHdG), which is a marker for oxidative stress. Results: Although urinary albumin excretion in the OLM and OLM+Ang II groups showed a tendency to be reduced compared to the vehicle group, it was significantly lower compared to the OLM+PD group. Urinary excretion of 8-OHdG was also significantly lower in the OLM and OLM+Ang II groups compared to the OLM+PD group. Conclusions: In diabetic nephropathy, the renoprotective effects of olmesartan are due not only to the blockade of AT(1) receptors, but also to a reduction in oxidative stress via stimulation of AT(2) receptors.

Copyright © 2011 S. Karger AG, Basel.

PMID: 21709422

===== References======

Tsukada K, Miyazaki T, Katoh H, Yoshikawa M, Masuda N, Ojima H, Tajima K, Fukai Y, Nakajima M, Kamiyama Y, Kuwano H, Tsukada O. Helicobacter pylori infection in hemodialysis patients. Hepatogastroenterology. 2003 Nov-Dec;50(54):2255-8.
[PMID: 14696511]
Agarwal R, Hynson JE, Hecht TJW, Light RP, Sinha AD. Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int. 2011 Nov;80(10):1073-9. doi: 10.1038/ki.2011.207. Epub 2011 Jun 29.
[PMID: 21716260] [DOI: 10.1038/ki.2011.207]
Proal AD, Albert PJ, Blaney GP, Lindseth IA, Benediktsson C, Marshall TG. Immunostimulation in the era of the metagenome. Cell Mol Immunol. 2011 May;8(3):213-25. doi: 10.1038/cmi.2010.77. Epub 2011 Jan 31.
[PMID: 21278764] [PMCID: 4076734] [DOI: 10.1038/cmi.2010.77]
Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant. 2003 Oct;18(10):1973-5. doi: 10.1093/ndt/gfg282.
[PMID: 13679467] [DOI: 10.1093/ndt/gfg282]
Nair S, O'Brien SV, Hayden K, Pandya B, Lisboa PJG, Hardy KJ, Wilding JPH. Effect of a cooked meat meal on serum creatinine and estimated glomerular filtration rate in diabetes-related kidney disease. Diabetes Care. 2014 Feb;37(2):483-7. doi: 10.2337/dc13-1770. Epub 2013 Sep 23.
[PMID: 24062331] [DOI: 10.2337/dc13-1770]
Pörsti IH. Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney. Kidney Int. 2008 Dec;74(11):1371-3. doi: 10.1038/ki.2008.424.
[PMID: 19008907] [DOI: 10.1038/ki.2008.424]
de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gómez-Campderá F, Luño J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12. doi: 10.1681/ASN.2006080916.
[PMID: 17130263] [DOI: 10.1681/ASN.2006080916]
Fliser D, Wagner K, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol. 2005 Apr;16(4):1135-40. doi: 10.1681/ASN.2004100852. Epub 2005 Feb 16.
[PMID: 15716329] [DOI: 10.1681/ASN.2004100852]
Wang XX, Jiang T, Levi M. Nuclear hormone receptors in diabetic nephropathy. Nat Rev Nephrol. 2010 Jun;6(6):342-51. doi: 10.1038/nrneph.2010.56. Epub 2010 Apr 27.
[PMID: 20421884] [DOI: 10.1038/nrneph.2010.56]
Eleftheriadis T, Antoniadi G, Liakopoulos V, Antoniadis N, Stefanidis I, Galaktidou G. Vitamin D receptor activators and response to injury in kidney diseases. J Nephrol. 2010 Sep-Oct;23(5):514-24.
[PMID: 20540037]
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JLJ, Januszewicz A. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6.
[PMID: 16508590] [DOI: 10.1097/01.hjh.0000202820.56201.e6]
Haller H, Ito S, Izzo JLJ, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.
[PMID: 21388309] [DOI: 10.1056/NEJMoa1007994]
Menne J, Izzo JLJ, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H, ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d.
[PMID: 22418908] [DOI: 10.1097/HJH.0b013e328351856d]
HealthCareRepublic. 2010. ARB slows onset of microalbuminuria.
Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl. 2006 Mar;24(1):S95-9. doi: 10.1097/01.hjh.0000220413.22482.36.
[PMID: 16601581] [DOI: 10.1097/01.hjh.0000220413.22482.36]
Mimura T, Takenaka T, Kanno Y, Moriwaki K, Okada H, Suzuki H. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens. 2008 Jan;22(1):38-47. doi: 10.1038/sj.jhh.1002264. Epub 2007 Jul 26.
[PMID: 17653243] [DOI: 10.1038/sj.jhh.1002264]
Chandar J, Abitbol C, Montané B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant. 2007 May;22(5):1332-7. doi: 10.1093/ndt/gfl839. Epub 2007 Feb 13.
[PMID: 17299000] [DOI: 10.1093/ndt/gfl839]
Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol. 2007 Mar;18(3):750-9. doi: 10.1681/ASN.2006070770. Epub 2007 Feb 7.
[PMID: 17287430] [DOI: 10.1681/ASN.2006070770]
Osawa H, Nakamura N, Shirato K, Nakamura M, Shimada M, Kumasaka R, Murakami R, Fujita T, Yamabe H, Okumura K. Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. Tohoku J Exp Med. 2006 May;209(1):7-13. doi: 10.1620/tjem.209.7.
[PMID: 16636517] [DOI: 10.1620/tjem.209.7]
Wang P, Fan M, Huang C, Feng J, Xiao Y, Fang Z, Zhang Y. Effect of losartan on slowing progression of chronic allograft nephropathy. Chin Med Sci J. 2005 Dec;20(4):231-6.
[PMID: 16422249]
Mahmood J, Khan F, Okada S, Kumagai N, Morioka T, Oite T. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int. 2006 Nov;70(9):1591-8. doi: 10.1038/sj.ki.5001872. Epub 2006 Sep 20.
[PMID: 16985512] [DOI: 10.1038/sj.ki.5001872]
Fan Y, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, Sun G, Kohno M, Fujita M, Abe Y, Nishiyama A. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res. 2006 Mar;29(3):169-78. doi: 10.1291/hypres.29.169.
[PMID: 16755152] [DOI: 10.1291/hypres.29.169]
home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.